Single-Cell Analysis
Europe · 5 shared keywords
Europe Spatial Transcriptomics Market Industry Trends and Forecast to 2034: Segmented by (Product, Application, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034
Overview
Europe · 2024–2034 · estimates
Market Dashboard
Values shown here are estimates. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.
Estimate 2024
$79.3 Mn
Estimated value
Estimate 2025
$89.9 Mn
17% of the global market
Projected 2034
$278.8 Mn 210.1%
Adds $188.9 Mn over 9 forecast years
CAGR 2025–2034
13.4%
Faster than 74% of 180 Pharmaceuticals markets here
Key players
5
Companies profiled
- Europe is 16.99% of the global market.
- Among regions, the largest is North America at $274.7 Mn.
- Fastest growing: APAC at 16.7% a year.
- Europe ranks 3rd of 6 by size among regions.
Market size projection
EuropeSource: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.
Value added each year
$188.9 Mn total, 2026–2034
Year-by-year market size, 2024–2034
| Year | Market size | Change that year | Since 2025 |
|---|---|---|---|
| 2024 (estimate) | $79.3 Mn | — | — |
| 2025 (base) | $89.9 Mn | +$10.6 Mn | — |
| 2026 (forecast) | $101.9 Mn | +$12.0 Mn | +13.4% |
| 2027 (forecast) | $115.6 Mn | +$13.7 Mn | +28.6% |
| 2028 (forecast) | $131.1 Mn | +$15.5 Mn | +45.8% |
| 2029 (forecast) | $148.6 Mn | +$17.6 Mn | +65.4% |
| 2030 (forecast) | $168.6 Mn | +$19.9 Mn | +87.5% |
| 2031 (forecast) | $191.2 Mn | +$22.6 Mn | +112.7% |
| 2032 (forecast) | $216.8 Mn | +$25.6 Mn | +141.2% |
| 2033 (forecast) | $245.8 Mn | +$29.0 Mn | +173.5% |
| 2034 (forecast) | $278.8 Mn | +$32.9 Mn | +210.1% |
Estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.
Same market worldwide
By geography
- Global $529.0 Mn
- North America $274.7 Mn
-
US
$233.0 Mn
- APAC $130.6 Mn
- Europe (this report) $89.9 Mn
-
China
$41.3 Mn
-
Canada
$36.2 Mn
-
Japan
$35.1 Mn
- Latin America $24.5 Mn
-
Germany
$21.3 Mn
- Middle East $20.6 Mn
-
Italy
$13.8 Mn
-
France
$13.0 Mn
-
Brazil
$13.3 Mn
-
UK
$12.1 Mn
-
Spain
$10.9 Mn
-
Ecuador
$9.9 Mn
-
India
$10.2 Mn
-
Saudi Arabia
$9.1 Mn
- Africa $8.6 Mn
-
Mexico
$8.3 Mn
-
Australia
$6.2 Mn
-
New Zealand
$4.9 Mn
-
Russia
$4.7 Mn
-
South Africa
$3.0 Mn
-
UAE
$2.7 Mn
-
Egypt
$1.6 Mn
-
Philippines
$1.2 Mn
-
Hong Kong
$0.9 Mn
-
Malaysia
$0.9 Mn
-
Singapore
$0.7 Mn
-
Thailand
$0.5 Mn
-
Kenya
$0.4 Mn
The Europe Spatial Transcriptomics Market Analysis Executive Summary
Spatial transcriptomics maps which genes are active in each part of a tissue sample, helping researchers understand cancer and disease.
Key segments of the spatial Transcriptomics market include product (Instruments, Consumables and Software) and application (Oncology, Neuroscience and Immunology).
Europe Spatial Transcriptomics Market Dynamics
Market Growth Drivers
The falling cost of DNA sequencing, more targeted medicines, large national genome programmes and growing use of genetic results in everyday care are driving the spatial Transcriptomics market.
Opportunity
Routine use of genomics in screening, pharmacy and primary care gives the spatial Transcriptomics market large room to grow.
Market Restraints
Data privacy concerns, limited reimbursement for some tests, shortages of genetic counsellors and complex data analysis hold back the spatial Transcriptomics market.
Competitive Landscape for Spatial Transcriptomics Market in Europe
The spatial Transcriptomics market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.
Key Players
Healthcare Policies and Regulatory Landscape for Spatial Transcriptomics Market in Europe
Policy changes and Reimbursement scenario
Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for spatial Transcriptomics. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in Europe.